SAN DIEGO, Jan. 27, 2017 /PRNewswire/ -- Johnson & Weaver, LLP has commenced an investigation concerning whether Novan, Inc. (NASDAQ: NOVN) violated federal securities laws. Novan is a clinical-stage drug development company, focusing on the development and commercialization of nitric oxide-based therapies in dermatology.
On January 27, 2017, trading of Novan stock was halted after the Company announced that two separate trials for its topical acne treatment produced different top-line outcomes. Novan stock was down over 70% prior to the stock trading halt.
If you are a Novan shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (firstname.lastname@example.org) by email or by phone at 619-814-4471. If emailing, please include a phone number where you can be reached.
About Johnson & Weaver, LLP:
Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.
Johnson & Weaver, LLP
Jim Baker, 619-814-4471
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/novan-novn-alert-shareholder-rights-law-firm-johnson--weaver-llp-initiates-investigation-of-novan-inc-encourages-any-investor-to-contact-the-firm-300398194.html
SOURCE Johnson & Weaver, LLP